PureTech Health plc(PRTC)Earnings, Financials & Key Ratios
PRTC•NASDAQ
$17.42
Price updated Jul 7, 2026
AboutPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Show more
- Revenue$5M-3.5%
- EBITDA-$95M+28.2%
- Net Income-$110M-305.1%
- EPS (Diluted)-46.00-2400.0%
- Gross Margin100%+284.1%
- EBITDA Margin-2042.84%+25.6%
- Operating Margin-2114.72%+25.0%
- Net Margin-2355.42%-312.5%
- ROE-30.76%-348.9%
PRTC Price & Volume
PureTech Health plc (PRTC) stock price & volume — 10-year historical chart
Loading chart...
PureTech Health Navigates Volatile Milestone Driven Growth
Investment Thesis • Updated 2025Q4
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial binary outcomes
Key Thesis Takeaways
- PureTech Health operates as a clinical-stage biotechnology incubator where value creation is primarily driven by the strategic divestiture of founded entities rather than recurring commercial revenue.
- While the company maintains a robust liquidity position with $254.1M in cash, investors must weigh the inherent risks of binary clinical trial outcomes against the company's history of lumpy milestone-dependent income.
- Future performance remains contingent on the platform's ability to replicate past exit successes, such as Karuna, while managing the structural operating deficits that saw R&D expenses reach $84.6M in 2022Q2.
Verdict Logic
while the company holds a strong liquidity buffer with a current ratio of 6.59, the persistent reliance on non-recurring milestone payments and the lack of predictable cash flow generation warrant a cautious approach until the internal pipeline demonstrates sustainable value.
PRTC Growth Metrics
PureTech Health plc (PRTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-8.83%
5 Years-10.99%
3 Years30.63%
TTM-53.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM52.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1176.19%
Return on Capital
10 Years-44.32%
5 Years-22.86%
3 Years-21.6%
Last Year-18.77%
PRTC Recent Earnings
PureTech Health plc (PRTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (80%)●Beat Revenue 3/12 qtrs (30%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$26.90-1286.6%
$1.94
Rev
$3M+47.2%
$2M
Q3 2025
Aug 28, 2025Metric
Actual
Est
EPS
$1.86+8.9%
$2.04
Rev
$2M-93.2%
$27M
Q2 2025
Apr 30, 2025Metric
Actual
Est
EPS
$0.35+112.5%
$2.83
Rev
$4M-86.7%
$30M
Q3 2024
Aug 28, 2024Metric
Actual
Est
EPS
$0.15+94.9%
$3.03
Rev
$288,000-96.2%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $26.90vs $1.94-1286.6% | $3Mvs $2M+47.2% |
| Q3 2025 | Aug 28, 2025 | $1.86vs $2.04+8.9% | $2Mvs $27M-93.2% |
| Q2 2025 | Apr 30, 2025 | $0.35vs $2.83+112.5% | $4Mvs $30M-86.7% |
| Q3 2024 | Aug 28, 2024 | $0.15vs $3.03+94.9% | $288,000vs $8M-96.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for PureTech Health plc (PRTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.42 | $42.04M | -0.38 | -3.5% | -2355.42% | -30.76% | — | |
| $36.31 | $26.12B | -84.44 | -71.57% | -3629.19% | -6.03% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $12.99 | $1.25B | -4.22 | — | — | -151.02% | — | |
| $3.84 | $1.72B | -2.67 | 26.92% | -844.46% | -54.32% | — | |
| $11.33 | $1.77B | -13.49 | -38.24% | -6450.76% | -63.58% | — |
Compare PRTC vs Peers
PureTech Health plc (PRTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PRTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRTC Frequently Asked Questions
PureTech Health plc (PRTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is PureTech Health plc's revenue?
PureTech Health plc (PRTC) reported $9.0M in revenue for fiscal year 2025. This represents a 13% increase from $7.9M in 2012.
How fast is PureTech Health plc growing?
PureTech Health plc (PRTC) saw revenue decline by 3.5% over the past year.
Is PRTC profitable?
PureTech Health plc (PRTC) reported a net loss of $56.0M for fiscal year 2025.
Dividend & Returns
What is PRTC's return on equity?
PureTech Health plc (PRTC) has a return on equity (ROE) of -30.8%. Negative ROE indicates the company is unprofitable.
What is PureTech Health plc's free cash flow?
PureTech Health plc (PRTC) had negative free cash flow of $218.8M in fiscal year 2025, likely due to heavy capital investments.